Vistagen therapeutics stock.

Find the latest Vistagen Therapeutics, Inc. (VTGN) stock quote, history, news and other vital information to help you with your stock trading and investing.

Vistagen therapeutics stock. Things To Know About Vistagen therapeutics stock.

Listed under the pharmaceutical preparations industry, VistaGen Therapeutics (NASDAQ:VTGN) focuses on developing new generation medicines for anxiety, depression and other central nervous system ...Listed under the pharmaceutical preparations industry, VistaGen Therapeutics (NASDAQ:VTGN) focuses on developing new generation medicines for anxiety, depression and other central nervous system ...SOUTH SAN FRANCISCO, Calif., August 07, 2023--Vistagen (NASDAQ: VTGN), a clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety ...Summary of all time highs, changes and price drops for Vistagen Therapeutics; Historical stock prices; Current Share Price: US$3.65: 52 Week High: …Aug. 8, 2023, 12:10 PM. There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on VistaGen Therapeutics ( VTGN – Research Report ), Madrigal ...

Moreover, Shawn Singh also holds US$83k worth of VistaGen Therapeutics stock directly under their own name. Component. 2022. 2021. Proportion (2022) Salary. US$563k. US$511k. 48%. Other. US$620k.The current Vistagen Therapeutics [ VTGN] share price is $3.38. The Score for VTGN is 29, which is 42% below its historic median score of 50, and infers higher risk than normal. VTGN is currently trading in the 20-30% percentile range relative to …Compare stocks to their industry peers at U.S. News Best Stocks. Money. Credit Cards. Best Of. ... VistaGen Therapeutics, Inc. is a late clinical-stage biopharmaceutical company, which engages in ...

Dec 1, 2023 · Anxiety-Focused Stock Vistagen Therapeutics Is An Undervalued Late-Stage Neurology Player: Analyst markets.businessinsider.com - November 14 at 6:25 PM: VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Q2 2024 Earnings Call Transcript finance.yahoo.com - November 11 at 5:51 PM The 50-day moving average is a frequently used data point by active investors and traders to understand the trend of a stock. It’s calculated by averaging the closing stock price over the previous 50 trading days. VistaGen Therapeutics Inc 50-day moving average is $3.73.

VistaGen Therapeutics Stock Forecast. All Analysts Top Analysts Stock Price Forecast. According to 2 stock analysts, the average 12-month stock price forecast for VTGN stock stock is $21, which predicts an increase of 475.34%. The lowest target is $12 and the highest is $30. On average, analysts rate VTGN stock stock as a strong buy.VistaGen Therapeutics Inc stock price live 3.650, this page displays NASDAQ VTGN stock exchange data. View the VTGN premarket stock price ahead of the market session or assess the after hours quote.Social Anxiety Disorder | Vistagen Therapeutics, Inc. Based on the 2021 National Health and Wellness Survey, social anxiety disorder (SAD) affects over 25 million Americans, with onset typically in the mid-teens or earlier, and is diagnosed slightly more frequently in females than males. SAD can be viewed as a series of acute, socially ...SOUTH SAN FRANCISCO, Calif., August 07, 2023 -- ( BUSINESS WIRE )--Vistagen (NASDAQ: VTGN), a clinical-stage biopharmaceutical company aiming to …

At one point Monday, investors shot up the value of Vistagen's stock (NASDAQ: VTGN) more than 1,300% to $24.71 per share before it settled at $13.05. Vistagen shares had closed Friday at $1.68.

Track VistaGen Therapeutics Inc (VTGN) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable insights from the community of like minded traders and investors

See today’s best-performing stocks on TipRanks >> Based on VistaGen Therapeutics’ latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $179.6 ...Vistagen ( NASDAQ: VTGN) said that a phase 3 study of fasedienol, a nasal spray to treat social anxiety disorder, met its primary and secondary endpoints. The stock is up ~905% in early Monday ...Medical, dental and vision premiums are paid at 100% for employees. Competitive wages. Unlimited paid time off (PTO) Paid holidays. Flexible work locations. Employee stock purchase plan. Follow us on LinkedIn. Apply to join Vistagen today. If you are interested in joining the Vistagen team, but do not see a job that matches your skill set ...Vistagen’s acquisition of Pherin will eliminate all future royalty and milestone payment obligations related to PH94B and PH10 and add three new pherine drug candidates to Vistagen’s pipeline. SOUTH SAN FRANCISCO, Calif. -- (BUSINESS WIRE)--Dec. 21, 2022-- Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to ...Stock Price Forecast. The 2 analysts offering 12-month price forecasts for Vistagen Therapeutics Inc have a median target of 12.00, with a high estimate of 12.00 and a low estimate of 12.00. The ... The VistaGen Therapeutics Inc stock price gained 7.16% on the last trading day (Friday, 24th Nov 2023), rising from $3.35 to $3.59. During the last trading day the stock fluctuated 8.30% from a day low at $3.37 to a day high of $3.65. The price has risen in 8 of the last 10 days and is up by 24.22% over the past 2 weeks.

Stifel Nicolaus initiated coverage on shares of Vistagen Therapeutics ( NASDAQ:VTGN – Free Report) in a research report sent to investors on Tuesday, Benzinga reports. The firm issued a buy rating and a $12.00 price target on the stock. Separately, Maxim Group reiterated a buy rating and issued a $30.00 price target on shares of …0.72. +0.045. +6.6667%. Get Vistagen Therapeutics Inc (VTGN:NASDAQ) real-time stock quotes, news, price and financial information from CNBC.In today’s fast-paced world, finding activities that provide relaxation and a sense of accomplishment is more important than ever. One such activity that has gained popularity in recent years is crafting and building.Aug 7, 2023 · SOUTH SAN FRANCISCO, Calif., August 07, 2023--Vistagen (NASDAQ: VTGN), a clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety ... Nov 24, 2023 · 33. Shawn Singh. https://www.vistagen.com. Vistagen Therapeutics, Inc., a late clinical-stage biopharmaceutical company, primarily focus to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders. The company’s pipeline includes six clinical stage product candidates ...

VistaGen Therapeutics, Inc. Common Stock (VTGN) Pre-Market Stock Quotes - Nasdaq offers pre-market quotes and pre-market activity data for US and global markets.

Vistagen Therapeutics Inc ( VTGN) is up 0.89% today. VTGN has an Overall Score of 58. Find out what this means to you and get the rest of the rankings on VTGN! VTGN stock closed at $3.37 and is up $0.03 during pre-market trading. Pre-market tends to be more volatile due to significantly lower volume as most investors only trade …Oct 2, 2023 · At a combined purchase price of $5.38 per share of common stock, accompanying T1 Warrant and accompanying T2 Warrant (as defined below), the offering consists of 15,010,810 shares of Vistagen common stock, accompanying warrants to purchase up to 9,294,022 shares of Vistagen common stock (or pre-funded warrants in lieu thereof) at an exercise ... Complete VistaGen Therapeutics Inc. stock information by Barron's. View real-time VTGN stock price and news, along with industry-best analysis.Get the latest Vistagen Therapeutics Inc (VTGN) stock quote, charts, news, and other financial information to help you make more informed trading and investment …In addition, VistaGen Therapeutics, Inc. has a VGM Score of F (this is a weighted average of the individual Style Scores which allow you to focus on the stocks that best fit your personal trading ...Vistagen Therapeutics, Inc. (VTGN.NASDAQ) : Stock quote, stock chart, quotes, analysis, advice, financials and news for Stock Vistagen Therapeutics, ...William Blair initiated coverage on VistaGen Therapeutics Inc (NASDAQ: VTGN), a clinical-stage biopharmaceutical company focused on developing next-generation treatment options for social anxiety ...The volume of stock shares issued by the company and in the hands of the public. This number entails how much is being traded in the open market. A decreasing ...

VistaGen Therapeutics’ core goal is to radically improve mental health and well-being worldwide. Beyond our drug development expertise, we aim to improve the mental health care ecosystem with better outcomes for patients, caregivers, advocates and communities.

SOUTH SAN FRANCISCO - Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (CNS) disorders, today announced new data, presented at the 2023 Anxiety and Depression Association of America (ADAA) Conference in Washington, D.C., that further supporting ...

fink. 10/14/23 1:04 PM. Post #4,990. Re: #4,989: @The_Q - A buddy told me this stock is $50-70. They have an impressive pipeline. But it's a pharma play. A time suck. They are in phase 3 for their first drug. Once they get those results they will submit to the FDA for approval. Based on short-term price targets offered by two analysts, the average price target for VistaGen Therapeutics, Inc. comes to $12.00. The forecasts range from a low of $12.00 to a high of $12.00 ...As of August 10, 2023, the Company had 9,362,444 shares of common stock outstanding. Conference Call. Vistagen will host a conference call and live audio webcast this afternoon at 4:30 p.m. Eastern Time to provide a corporate update. U.S. Dial-in ... VISTAGEN THERAPEUTICS, INC.Jul 22, 2022 · VistaGen Therapeutics stock is diving lower on poor results from a clinical trial.; This saw a Phase 3 study of PH94B fail to meet its primary endpoint. This has heavy trading dragging the company ... The latest price target for . Vistagen Therapeutics (NASDAQ: VTGN) was reported by Maxim Group on September 5, 2023.The analyst firm set a price target for $30.00 expecting VTGN to rise to within ...VistaGen Therapeutics ( NASDAQ: VTGN) jumped ~17% on Wednesday morning after announcing data from a Phase 3 trial for its experimental nasal spray for social anxiety disorder (SAD), fasedienol ...VistaGen Therapeutics has raised a total of. $154.8M. in funding over 8 rounds. Their latest funding was raised on Oct 2, 2023 from a Post-IPO Equity round. VistaGen Therapeutics is registered under the ticker NASDAQ:VTGN . VistaGen Therapeutics is funded by 9 investors. BVF Partners and TCG Crossover are the most recent investors.Dec 1, 2023 · Valuation metrics show that VistaGen Therapeutics, Inc. may be overvalued. Its Value Score of F indicates it would be a bad pick for value investors. The financial health and growth prospects of ... VistaGen Therapeutics’ core goal is to radically improve mental health and well-being worldwide. Beyond our drug development expertise, we aim to improve the mental health care ecosystem with better outcomes for patients, caregivers, advocates and communities.Find real-time VTGN - Vistagen Therapeutics Inc stock quotes, company profile, news and forecasts from CNN Business.

Listed under the pharmaceutical preparations industry, VistaGen Therapeutics (NASDAQ:VTGN) focuses on developing new generation medicines for anxiety, depression and other central nervous system ...Medical, dental and vision premiums are paid at 100% for employees. Competitive wages. Unlimited paid time off (PTO) Paid holidays. Flexible work locations. Employee stock purchase plan. Follow us on LinkedIn. Apply to join Vistagen today. If you are interested in joining the Vistagen team, but do not see a job that matches your skill set ...VISTAGEN THERAPEUTICS, INC. CONSOLIDATED BALANCE SHEETS (Amounts in dollars, except share amounts) June 30, March 31, 2023 2023 (Unaudited) ASSETS: Current assets: Cash and cash equivalents $ 9,622,300 $ 16,637,600 Prepaid expenses and other current assets 1,889,400 802,700As of February 7, 2023, the Company had 219,326,526 shares of common stock outstanding, which reflects the issuance of approximately 12.4 million unregistered shares of common stock associated with the Pherin Pharmaceuticals transaction. Conference Call. ... VISTAGEN THERAPEUTICS, INC.Instagram:https://instagram. what are tax yield investmentsfirst horizon bank stock pricea 1 tradingt rowe dividend growth Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (CNS) disorders, today announced positive feedback from its recent engagement with the U.S. Food and Drug Administration (FDA) regarding the use of the Liebowitz Social Anxiety Scale (LSAS) as the ... cxapp stockoption trading example Stock analysis for Vistagen Therapeutics Inc (VTGN:NASDAQ CM) including stock price, stock chart, company news, key statistics, fundamentals and company profile. where to trade e mini futures The upgrade of VistaGen Therapeutics, Inc. to a Zacks Rank #2 positions it in the top 20% of the Zacks-covered stocks in terms of estimate revisions, implying that the stock might move higher in ...Nov 30, 2023 · According to the issued ratings of 2 analysts in the last year, the consensus rating for Vistagen Therapeutics stock is Buy based on the current 2 buy ratings for VTGN. The average twelve-month price prediction for Vistagen Therapeutics is $21.00 with a high price target of $30.00 and a low price target of $12.00. Vistagen Therapeutics, Inc. 3.6900 ... is selling $2 billion of stock in Las Vegas Sands Corp. so the family can acquire a majority stake in the Dallas Mavericks NBA franchise from Mark Cuban.Most ...